The Experts below are selected from a list of 21285 Experts worldwide ranked by ideXlab platform
Kevin N Dalby - One of the best experts on this subject based on the ideXlab platform.
-
abstract 2172 quantification of erk activity in cancer cell lysates and Tumor Extract using differential sensing methods
Cancer Research, 2019Co-Authors: Diana Zamoraolivares, Tamer S Kaoud, Lingyu Zeng, Mitchell Telles, Eric V Anslyn, Kevin N DalbyAbstract:The activity of protein kinases in biological samples is typically estimated by determining the phosphorylation status of either the kinase itself, or a known cellular substrate. This is typically evaluated by multi-step western blotting, or proteomics procedures. Such procedures typically provide qualitative estimates of the modifications in question. While immunoblotting and proteomics procedures can be used in a quantitative manner, their complicated workflow diminishes reproducibility. Futhermore, modifications do not necessarily correlate closely with a protein kinase’s activity. The motivation for this work was to assess the potential of a peptide array to quantify ERK activity in cancer cell lines and Tumor samples, without the need to suppress related kinase activities. This work shows that a library of cross-reactive peptide-based biosensors, along with chemometric analysis can be used to profile a kinase activity in cancer cell lines. Significantly, the array is suitable for quantifying unknown levels of ERK activity in unfractionated cancer cell lysates and Tumor samples using a multivariate regression model. The predicted values provided by our model were found to be comparable to those obtained by immune complex kinase assays. Note: This abstract was not presented at the meeting. Citation Format: Diana Zamora-Olivares, Tamer S. Kaoud, Lingyu Zeng, Mitchell Telles, Eric V. Anslyn, Kevin N. Dalby. Quantification of ERK activity in cancer cell lysates and Tumor Extract using differential sensing methods [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2172.
H F Seigler - One of the best experts on this subject based on the ideXlab platform.
-
pulsing of dendritic cells with cell lysates from either b16 melanoma or mca 106 fibrosarcoma yields equally effective vaccines against b16 Tumors in mice
Journal of Surgical Oncology, 1998Co-Authors: Pierre Dematos, Zeinab Abdelwahab, Carol E Vervaert, Dina Hester, H F SeiglerAbstract:Background and Objectives: Dendritic cells (DC) pulsed in vitro with a variety of antigens have proved effective in producing specific antiTumor effects in vivo. Experimental evidence from other laboratories has confirmed that shared antigens can be encountered in histologically distinct Tumors. In our experiments, we set out to evaluate the immunotherapeutic potential of vaccines consisting of DC pulsed with MCA-106 fibrosarcoma or B16 melanoma cell lysates and to determine whether a cross-reactivity exists between the two Tumors. Methods DC were prepared from the bone marrow of C57BL/6 (B6) mice by culturing progenitor cells in murine granulocyte-macrophage colony-stimulating factor (GM-CSF). They were separated into three equal groups and were either pulsed with B16 melanoma cell lysates (BDC), pulsed with Tumor Extract from the syngeneic fibrosarcoma MCA-106 (MDC), or left unpulsed (UDC). DC were then used to immunize three groups of mice, with all mice receiving two weekly intravenous (IV) doses of 1 × 106 DC from their respective preparations on days −14 and −7. A fourth group of control mice were left untreated. On day 0, all mice were challenged with subcutaneous injections of 1 × 105 B16 and 1 × 105 MCA Tumor cells, administered in the left and right thighs, respectively. After the inoculations, the mice were monitored closely with respect to Tumor growth and survival. Results The MDC mice developed specific cellular immunity directed against not only MCA-106 Tumor cells, but also against B16 melanoma, as measured through chromium-release assays of splenocyte preparations, while remaining ineffective at killing both L929 fibroblasts and CT26 Tumor cells. By day 30 after Tumor inoculations, control mice manifested the largest B16 Tumor volumes at a mean of 2185 mm3, followed by the UDC, MDC, and BDC groups at 92 mm3 (P = 0.00008), 3 mm3 (P = 0.000002), and 2 mm3 (P = 0.00004), respectively. The survival data mirrored this pattern, with control animals displaying the shortest mean survival time (37.1 ± 4.0 days), followed by UDC (44.8 ± 6.6), MDC (56.2 ± 14.7), and BDC (56.4 ± 18.3) animals. No significant differences were noted between MCA-106 and B16 cell lysate-pulsed DC vaccines with respect to their abilities to inhibit B16 Tumor growth and to prolong survival. These findings were confirmed using a B16 pulmonary metastasis model. Likewise, vaccination with interferon-γ gene-modified MCA-106 Tumor cells was shown to be effective at protecting against a subsequent subcutaneous B16 Tumor challenge in 3 of 4 mice observed. Conclusions These results demonstrate that immunization with antigen-pulsed DC confers cellular immunity, retards Tumor growth, and prolongs the survival of Tumor-challenged mice. The ability of MCA-106 cell lysate-pulsed DC vaccines to inhibit the growth of subcutaneous B16 Tumors also suggests the presence of shared Tumor-associated antigens between these two histologically distinct Tumors. J. Surg. Oncol. 1998;68:79–91. © 1998 Wiley-Liss, Inc.
Eli Gilboa - One of the best experts on this subject based on the ideXlab platform.
-
bone marrow generated dendritic cells pulsed with Tumor Extracts or Tumor rna induce antiTumor immunity against central nervous system Tumors
Journal of Experimental Medicine, 1997Co-Authors: David M Ashley, Brenda Faiola, Smita K Nair, Laura P Hale, Darell D Bigner, Eli GilboaAbstract:Recent studies have shown that the brain is not a barrier to successful active immunotherapy that uses gene-modified autologous Tumor cell vaccines. In this study, we compared the efficacy of two types of vaccines for the treatment of Tumors within the central nervous system (CNS): dendritic cell (DC)-based vaccines pulsed with either Tumor Extract or Tumor RNA, and cytokine gene–modified Tumor vaccines. Using the B16/F10 murine melanoma (B16) as a model for CNS Tumor, we show that vaccination with bone marrow–generated DCs, pulsed with either B16 cell Extract or B16 total RNA, can induce specific cytotoxic T lymphocytes against B16 Tumor cells. Both types of DC vaccines were able to protect animals from Tumors located in the CNS. DC-based vaccines also led to prolonged survival in mice with Tumors placed before the initiation of vaccine therapy. The DC-based vaccines were at least as effective, if not more so, as vaccines containing B16 Tumor cells in which the granulocytic macrophage colony-stimulating factor gene had been modified. These data support the use of DC-based vaccines for the treatment of patients with CNS Tumors.
Diana Zamoraolivares - One of the best experts on this subject based on the ideXlab platform.
-
abstract 2172 quantification of erk activity in cancer cell lysates and Tumor Extract using differential sensing methods
Cancer Research, 2019Co-Authors: Diana Zamoraolivares, Tamer S Kaoud, Lingyu Zeng, Mitchell Telles, Eric V Anslyn, Kevin N DalbyAbstract:The activity of protein kinases in biological samples is typically estimated by determining the phosphorylation status of either the kinase itself, or a known cellular substrate. This is typically evaluated by multi-step western blotting, or proteomics procedures. Such procedures typically provide qualitative estimates of the modifications in question. While immunoblotting and proteomics procedures can be used in a quantitative manner, their complicated workflow diminishes reproducibility. Futhermore, modifications do not necessarily correlate closely with a protein kinase’s activity. The motivation for this work was to assess the potential of a peptide array to quantify ERK activity in cancer cell lines and Tumor samples, without the need to suppress related kinase activities. This work shows that a library of cross-reactive peptide-based biosensors, along with chemometric analysis can be used to profile a kinase activity in cancer cell lines. Significantly, the array is suitable for quantifying unknown levels of ERK activity in unfractionated cancer cell lysates and Tumor samples using a multivariate regression model. The predicted values provided by our model were found to be comparable to those obtained by immune complex kinase assays. Note: This abstract was not presented at the meeting. Citation Format: Diana Zamora-Olivares, Tamer S. Kaoud, Lingyu Zeng, Mitchell Telles, Eric V. Anslyn, Kevin N. Dalby. Quantification of ERK activity in cancer cell lysates and Tumor Extract using differential sensing methods [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2172.
Pierre Dematos - One of the best experts on this subject based on the ideXlab platform.
-
pulsing of dendritic cells with cell lysates from either b16 melanoma or mca 106 fibrosarcoma yields equally effective vaccines against b16 Tumors in mice
Journal of Surgical Oncology, 1998Co-Authors: Pierre Dematos, Zeinab Abdelwahab, Carol E Vervaert, Dina Hester, H F SeiglerAbstract:Background and Objectives: Dendritic cells (DC) pulsed in vitro with a variety of antigens have proved effective in producing specific antiTumor effects in vivo. Experimental evidence from other laboratories has confirmed that shared antigens can be encountered in histologically distinct Tumors. In our experiments, we set out to evaluate the immunotherapeutic potential of vaccines consisting of DC pulsed with MCA-106 fibrosarcoma or B16 melanoma cell lysates and to determine whether a cross-reactivity exists between the two Tumors. Methods DC were prepared from the bone marrow of C57BL/6 (B6) mice by culturing progenitor cells in murine granulocyte-macrophage colony-stimulating factor (GM-CSF). They were separated into three equal groups and were either pulsed with B16 melanoma cell lysates (BDC), pulsed with Tumor Extract from the syngeneic fibrosarcoma MCA-106 (MDC), or left unpulsed (UDC). DC were then used to immunize three groups of mice, with all mice receiving two weekly intravenous (IV) doses of 1 × 106 DC from their respective preparations on days −14 and −7. A fourth group of control mice were left untreated. On day 0, all mice were challenged with subcutaneous injections of 1 × 105 B16 and 1 × 105 MCA Tumor cells, administered in the left and right thighs, respectively. After the inoculations, the mice were monitored closely with respect to Tumor growth and survival. Results The MDC mice developed specific cellular immunity directed against not only MCA-106 Tumor cells, but also against B16 melanoma, as measured through chromium-release assays of splenocyte preparations, while remaining ineffective at killing both L929 fibroblasts and CT26 Tumor cells. By day 30 after Tumor inoculations, control mice manifested the largest B16 Tumor volumes at a mean of 2185 mm3, followed by the UDC, MDC, and BDC groups at 92 mm3 (P = 0.00008), 3 mm3 (P = 0.000002), and 2 mm3 (P = 0.00004), respectively. The survival data mirrored this pattern, with control animals displaying the shortest mean survival time (37.1 ± 4.0 days), followed by UDC (44.8 ± 6.6), MDC (56.2 ± 14.7), and BDC (56.4 ± 18.3) animals. No significant differences were noted between MCA-106 and B16 cell lysate-pulsed DC vaccines with respect to their abilities to inhibit B16 Tumor growth and to prolong survival. These findings were confirmed using a B16 pulmonary metastasis model. Likewise, vaccination with interferon-γ gene-modified MCA-106 Tumor cells was shown to be effective at protecting against a subsequent subcutaneous B16 Tumor challenge in 3 of 4 mice observed. Conclusions These results demonstrate that immunization with antigen-pulsed DC confers cellular immunity, retards Tumor growth, and prolongs the survival of Tumor-challenged mice. The ability of MCA-106 cell lysate-pulsed DC vaccines to inhibit the growth of subcutaneous B16 Tumors also suggests the presence of shared Tumor-associated antigens between these two histologically distinct Tumors. J. Surg. Oncol. 1998;68:79–91. © 1998 Wiley-Liss, Inc.
